Associated Papers
MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.
Friker LL et al.
Acta Neuropathologica, 2025
39894875 (PubMed )
Supplement: 401_2025_2846_MOESM1_ESM.xlsx › Sheet1
Diagnosis, Treatment, and Prognosis of Patients with Primary Familial Gastrointestinal Stromal Tumor: A Case Report and Literature Review.
Yan M et al.
The Oncologist, 2023
37311038 (PubMed )
Supplement: oyad168_suppl_supplementary_table_s1.docx
A Rare PDGFRA Exon 15 Germline Mutation Identified in a Patient With Phenotypic Manifestations Concerning for GIST-Plus Syndrome: A Case Report and Review of Literature.
Wang C et al.
International Journal of Surgical Pathology, 2023
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.
Wong NACS et al.
Cancer Genetics, 2022
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group.
Toss A et al.
Current Oncology Reports, 2022
Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation.
Armstrong AE et al.
Pediatric Blood & Cancer, 2019
Implementation of genomic medicine for gastrointestinal tumors.
Furukawa Y
Annals of Gastroenterological Surgery, 2018
Familial PDGFRA-mutation syndrome: somatic and gastrointestinal phenotype.
Manley PN et al.
Human Pathology, 2018
High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H et al.
Human Pathology, 2014
Gastrointestinal stromal tumors (GISTs): role of CD 117 and PDGFRA Golgi-like staining pattern in the recognition of mutational status.
Jaramillo S et al.
Revista Espanola De Enfermedades Digestivas, 2012
Progress in molecular diagnostics of gastrointestinal stromal tumors.
Daum O et al.
Expert Opinion on Medical Diagnostics, 2007
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Debiec-Rychter M et al.
European Journal of Cancer (oxford, England : 1990), 2006
Select a paper to view details